Prosecution Insights
Last updated: April 19, 2026
Application No. 18/028,669

SURFACE MODIFIED PARTICLES

Non-Final OA §112
Filed
Mar 27, 2023
Examiner
GIERE, REBECCA M
Art Unit
1677
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
UNIVERZITA PALACKEHO V OLOMOUCI
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
3y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
364 granted / 495 resolved
+13.5% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
42 currently pending
Career history
537
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
42.0%
+2.0% vs TC avg
§102
21.3%
-18.7% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 495 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of Claims Claims 1-9 are pending and have been examined. Priority This application, Serial No. 18/028,669 (PGPub: US2023/0366886) was filed 03/27/2023. This application is a 371 of PCT/CZ2021/050103 filed 09/29/2021. This application claims priority to Czechia PV 2020-535 filed 09/29/2020. Information Disclosure Statements The Information Disclosure Statement filed 03/27/2023 has been considered by the Examiner. Claim Objections Claim 5 is objected to because of the following informalities: Claim 5 should be corrected to say “The process according to claim 3”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 1, the phrase "such as" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 2, the phrases "more preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 3, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 4, the claim is drawn to “the process…according to claim 1”, however, claim 1 has not recited a process and thus the claim lacks antecedent basis. Regarding claim 4, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 8, the phrase "preferably" renders the claim indefinite because it is unclear whether the limitations following the phrase are part of the claimed invention. See MPEP § 2173.05(d). Regarding claim 9, the claim is drawn to the process of claim 1 and is indefinite since claim 1 is drawn to surface-modified particles and not a process. Claim 9 should be amended to be dependent on the particles, for example, “A process of using the surface-modified particles of claim 1 for in vitro detection…”. Regarding claim 9, the claim states that detection includes interaction of modified particles with said biomolecules. However, claim 1 has an alternative where z in the structure could be equal to 0. It is unclear how, if z=0 (thus deleting the Z monomer and attached R group), the biomolecules would be able to be conjugated to the claimed modified particles. State of the Prior Art The prior art fails to teach the claimed surface-modified particles with an outer shell consisting of a layer of a polymer of Formula II. WO 2010/139942 teaches the modification of nanoparticles with a linker comprising lipoic acid (via two thiol groups) and polyethylene glycol (page 7, line 8, claims 1, 15 and Figures 1-2), as seen in the first half of the Formula II structure). However, the reference does not teach the incorporation of a brush polymer comprising isopropanol amide, seen in the second half of Formula II structure. Yang et al. (Chem. Mater. 2017, 29, pages 8757-8765) teaches in vivo nanopolymersomes incorporating the polymer structure seen in Figure 1. However, Yang fails to specifically teach particles having a polymer outershell with a structure of Formula II. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REBECCA M GIERE whose telephone number is (571)272-5084. The examiner can normally be reached M-F 8:30-4:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bao-Thuy L Nguyen can be reached at 571-272-0824. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REBECCA M GIERE/Primary Examiner, Art Unit 1677
Read full office action

Prosecution Timeline

Mar 27, 2023
Application Filed
Mar 06, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12571804
AUTOMATIC TEST CARD FOR MULTI-BLOOD GROUP SYSTEM AND TEST METHOD
2y 5m to grant Granted Mar 10, 2026
Patent 12571035
METHOD OF TARGET MOLECULE CHARACTERISATION USING A MOLECULAR PORE
2y 5m to grant Granted Mar 10, 2026
Patent 12560599
SAMPLE CLARIFICATION AND REDUCTION OF BACKGROUND FLUORESCENCE FOR FLUORESCENT DETECTION OF ANALYTES
2y 5m to grant Granted Feb 24, 2026
Patent 12544755
WHOLE-PROCESS BIOLOGICAL DETECTION DEVICE
2y 5m to grant Granted Feb 10, 2026
Patent 12529656
BIOMOLECULAR ANALYSIS METHOD AND BIOMOLECULAR ANALYZER
2y 5m to grant Granted Jan 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+32.8%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 495 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month